Recently news has been circulating that condemns Turing Pharmaceuticals for price gouging United States consumers of pyrimethamine1 an antimalarial which sells for under ten cents per dose in markets other than the United States where generic forms are available. Pyrimethamine is very popular in areas of the world where malaria is endemic due to its efficacy against most strains of the falciparum and vivax species of the Plasmodium malaria parasite, but in the United States it is typically used to treat toxoplasmosis in immunocompromised patients making it a niche treatment. Turing Pharmaceuticals managed to get a contract to exclusively market pyrimethamine in the United States thanks to FDA regulations. Because the FDA allows them exclusive marketing rights they can set prices arbitrarily, and if they can they must. Continue reading
trade name Daparim, released in 1953 ↩